Clinical Report: Lilly’s $7B In Vivo CAR-T Bet

Overview

Eli Lilly's acquisition of Kelonia Therapeutics for $7 billion aims to enhance its in vivo CAR-T cell therapy capabilities. The lead candidate, KLN-1010, is currently in Phase 1 trials and shows promising early efficacy and tolerability in treating multiple myeloma.

Background

The development of in vivo CAR-T therapies represents a significant advancement in cancer treatment, potentially simplifying the manufacturing process and improving patient access. Traditional ex vivo CAR-T therapies involve complex procedures that can delay treatment. The growing interest in in vivo strategies reflects a need for more efficient and accessible cancer therapies.

Data Highlights

No numerical data available in the provided material.

Key Findings

Clinical Implications

Detail how in vivo CAR-T therapies could specifically change treatment protocols.

Conclusion

The move towards in vivo CAR-T therapies signifies a pivotal shift in cancer treatment, with potential benefits in accessibility and efficiency. Continued monitoring of clinical outcomes will be essential as these therapies develop.

Related Resources & Content

1. Franklin / MDSpire, Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
2. The ASCO Post, Early Findings From First Human Study of In Vivo CAR T in Myeloma
3. The ASCO Post, CAR T-Cell Therapy for DLBCL: At the Crossroads of Hype and Reality
4. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
5. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PubMed
6. In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery
7. Franklin / MDSpire — Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
8. the medicine maker — Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
9. Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
10. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
11. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PubMed
12. In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery